Hier finden Sie Publikationen unserer Mitarbeiter.


Fichtner I.; Klinghammer K.; Behrens D.; Flechsig S.; Rolff J.; Becker M.; Wulf-Goldenberg A.; Stecklum M.; Rivera M.; Brzezicha B.; Jandrig B.; Hoffmann J.
Animal models for personalized treatment options
International Journal of Clinical Pharmacology and Therapeutics 55 (8): 698-700 (2017-08)

Hendriks H.R.; Govaerts A.S.; Fichtner I.; Burtles S.; Westwell A.D.; Peters G.J.
Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative
British Journal of Cancer 117 (2): 195-202 (2017-07-11)


Schmid F.; Wang Q.; Huska M.R.; Andrade-Navarro M.A.; Lemm M.; Fichtner I.; Dahlmann M.; Kobelt D.; Walther W.; Smith J.; Schlag P.M.; Stein U.
SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival
Oncogene 35 (46): 5942-5952 (2016-11-17)

Orthmann A.; Peiker L.; Fichtner I.; Hoffmann A.; Hilger R.A.; Zeisig R.
Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes
Journal of Biomedical Nanotechnology 12 (1): 56-68 (2016-01)


Klinghammer K.; Raguse J.D.; Plath T.; Albers A.E.; Joehrens K.; Zakarneh A.; Brzezicha B.; Wulf-Goldenberg A.; Keilholz U.; Hoffmann J.; Fichtner I.
A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option
International Journal of Cancer 136 (12): 2940-2948 (2015-06-15)

Testen A; Podlipec R; Mravljak J; Orthmann A; Sentjurc M; Zeisig R; Strancar J; Koklic T
How perifosine affects liposome-encapsulated drug delivery across a cell barrier
Therapeutic Delivery 6 (4): 423-441 (2015-04)

Stecklum M.; Wulf-Goldenberg A.; Purfuerst B.; Siegert A.; Keil M.; Eckert K.; Fichtner I.
Cell differentiation mediated by co-culture of human umbilical cord blood stem cells with murine hepatic cells
In Vitro Cellular & Developmental Biology Animal 51 (2): 183-191 (2015-02)


Huelsmann H.J.; Rolff J.; Bender C.; Jarahian M.; Korf U.; Herwig R.; Froehlich H.; Thomas M.; Merk J.; Fichtner I.; Sueltmann H.; Kuner R.
Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib
Lung Cancer 86 (2): 151-157 (2014-11)

Vallespi M.G.; Pimentel G.; Cabrales-Rico A.; Garza J.; Oliva B.; Mendoza O.; Gomez Y.; Basaco T.; Sanchez I.; Calderon C.; Rodriguez J.C.; Markelova M.R.; Fichtner I.; Astrada S.; Bollati-Fogolín M.; Garay H.E.; Reyes O.
Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models
Journal of Peptide Science 20 (11): 850-859 (2014-11)

Walther W.; Fichtner I.; Hackenberg F.; Streciwilk W.; Tacke M.
In vitro and in vivo investigations into the carbene copper bromide anticancer drug candidate WBC4
Letters in Drug Design & Discovery 11 (7): 825-832 (2014-08)

Belz K.; Schoeneberger H.; Wehner S.; Weigert A.; Boenig H.; Klingebiel T.; Fichtner I.; Fulda S.
Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly
Blood 124 (2): 240-250 (2014-07-10)

Friesen C.; Hormann I.; Roscher M.; Fichtner I.; Alt A.; Hilger R.; Debatin K.M.; Miltner E.
Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma
Cell Cycle 13 (10): 1560-1570 (2014-05-15)

Redmer T.; Welte Y.; Behrens D.; Fichtner I.; Przybilla D.; Wruck W.; Yaspo M.L.; Lehrach H.; Schaefer R.; Regenbrecht C.R.A.
The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells
PLoS ONE 9 (5): e92596 (2014-05-05)

Kobelt D.; Aumann J.; Schmidt M.; Wittig B.; Fichtner I.; Behrens D.; Lemm M.; Freundt G.; Schlag P.M.; Walther W.
Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector
Molecular Oncology 8 (3): 609-619 (2014-05)


Holland J.D.; Gyoerffy B.; Vogel R.; Eckert K.; Valenti G.; Fang L.; Lohneis P.; Elezkurtaj S.; Ziebold U.; Birchmeier W.
Combined Wnt/{beta}-catenin, met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome
Cell Reports 5 (5): 1214-1227 (2013-12-12)

Loeschmann N.; Michaelis M.; Rothweiler F.; Zehner R.; Cinatl J.; Voges Y.; Sharifi M.; Riecken K.; Meyer J.; von Deimling A.; Fichtner I.; Ghafourian T.; Westermann F.; Cinatl Jr. J.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs
Translational Oncology 6 (6): 685-696 (2013-12)

Walther W.; Schmeer M.; Kobelt D.; Baier R.; Harder A.; Walhorn V.; Anselmetti D.; Aumann J.; Fichtner I.; Schleef M.
A seven-year storage report of good manufacturing practice-grade naked plasmid DNA: stability, topology, and in vitro/in vivo functional analysis
Human Gene Therapy Clinical Development 24 (4): 147-153 (2013-12)

Stachelscheid H.; Wulf-Goldenberg A.; Eckert K.; Jensen J.; Edsbagge J.; Bjoerquist P.; Rivero M.; Strehl R.; Jozefczuk J.; Prigione A.; Adjaye J.; Urbaniak T.; Bussmann P.; Zeilinger K.; Gerlach J.C.
Teratoma formation of human embryonic stem cells in three-dimensional perfusion culture bioreactors
Journal of Tissue Engineering and Regenerative Medicine 7 (9): 729-741 (2013-09)

Gries J.; Schumacher D.; Arand J.; Lutsik P.; Markelova M.R.; Fichtner I.; Walter J.; Sers C.; Tierling S.
Bi-PROF: bisulfite profiling of target regions using 454 GS FLX Titanium technology
Epigenetics 8 (7): 765-771 (2013-07)

Walther W.; Fichtner I.; Deally A.; Hogan M.; Tacke M.
The activity of titanocene T against xenografted Caki-1 tumors
Letters in Drug Design & Discovery 10 (5): 375-381 (2013-06)

Friesen C.; Roscher M.; Hormann I.; Fichtner I.; Alt A.; Hilger R.A.; Debatin K.M.; Miltner E.
Cell death sensitization of leukemia cells by opioid receptor activation
Oncotarget 4 (5): 677-690 (2013-04-16)

Bastian L.; Hof J.; Pfau M.; Fichtner I.; Eckert C.; Henze G.; Prada J.; von Stackelberg A.; Seeger K.; Shalapour S.
Synergistic activity of bortezomib and HDACis in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT and NF-{kappa}B
Clinical Cancer Research 19 (6): 1445-1457 (2013-03-15)

Kratz F.; Azab S.; Zeisig R.; Fichtner I.; Warnecke A.
Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model
International Journal of Pharmaceutics 441 (1-2): 499-506 (2013-01-30)


Fichtner I.; Cinatl J.; Michaelis M.; Sanders L.C.; Hilger R.; Kennedy B.N.; Reynolds A.L.; Hackenberg F.; Lally G.; Quinn S.J.; McRae I.; Tacke M.
In vitro and in vivo investigations into the carbene silver acetate anticancer drug candidate SBC1
Letters in Drug Design & Discovery 9 (9): 815-822 (2012-11)

Abu Ajaj K.; El-Abadla N.; Welker P.; Azab S.; Zeisig R.; Fichtner I.; Kratz F.
Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative
European Journal of Cancer 48 (13): 2054-2065 (2012-09)

Dahlmann M.; Sack U.; Herrmann P.; Lemm M.; Fichtner I.; Schlag P.M.; Stein U.
Systemic shRNA mediated knock down of S100A4 in colorectal cancer xenografted mice reduces metastasis formation
Oncotarget 3 (8): 783-797 (2012-08-07)

Abolhassani M.; Guais A.; Sanders E.; Campion F.; Fichtner I.; Bonte J.; Baronzio G.; Fiorentini G.; Israel M.; Schwartz L.
Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice
Investigational New Drugs 30 (4): 1331-1342 (2012-08)

Kratz F.; Fichtner I.; Graeser R.
Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model
Investigational New Drugs 30 (4): 1743-1749 (2012-08)

Orthmann A.; Zeisig R.; Suess R.; Lorenz D.; Lemm M.; Fichtner I.
Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result
Pharmaceutical Research 29 (7): 1949-1959 (2012-07)

McCann M.; Santos A.L.S.; da Silva B.A.; Romanos M.T.V.; Pyrrho A.S.; Devereux M.; Kavanagh K.; Fichtner I.; Kellett A.
In vitro and in vivo studies into the biological activities of 1,10-phenanthroline, 1,10-phenanthroline-5,6-dione and its copper(II) and silver(I) complexes
Toxicology Research 1 (1): 47-54 (2012-07)

Sokolenko A.P.; Iyevleva A.G.; Preobrazhenskaya E.V.; Mitiushkina N.V.; Abysheva S.N.; Suspitsin E.N.; Kuligina E.S.; Gorodnova T.V.; Pfeifer W.; Togo A.V.; Turkevich E.A.; Ivantsov A.O.; Voskresenskiy D.V.; Dolmatov G.D.; Bit-Sava E.M.; Matsko D.E.; Semiglazov V.F.; Fichtner I.; Larionov A.A.; Kuznetsov S.G.; Antoniou A.C.; Imyanitov E.N.
High prevalence and breast cancer predisposing role of the BLMc.1642 C>T (Q548X) mutation in Russia
International Journal of Cancer 130 (12): 2867-2873 (2012-06-15)

Walther W.; Petkov S.; Kuvardina O.N.; Aumann J.; Kobelt D.; Fichtner I.; Lemm M.; Piontek J.; Blasig I.E.; Stein U.; Schlag P.M.
Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors
Gene Therapy 19 (5): 494-503 (2012-05)

Schlesinger M.; Schmitz P.; Zeisig R.; Naggi A.; Torri G.; Casu B.; Bendas G.
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives
Thrombosis Research 129 (5): 603-610 (2012-05)

Wulf-Goldenberg A.; Keil M.; Fichtner I.; Eckert K.
Intrahepatic transplantation of CD34(+) cord blood stem cells into newborn and adult NOD/SCID mice induce differential organ engraftment
Tissue & Cell 44 (2): 80-86 (2012-04)

Keil M.; Siegert A.; Eckert K.; Gerlach J.; Haider W.; Fichtner I.
Transcriptional expression profile of cultured human embryonic stem cells in vitro and in vivo
In Vitro Cellular & Developmental Biology Animal 48 (3): 165-174 (2012-03)


Sack U.; Walther W.; Scudiero D.; Selby M.; Aumann J.; Lemos C.; Fichtner I.; Schlag P.M.; Shoemaker R.H.; Stein U.
S100A4-induced cell motility and metastasis is restricted by the Wnt/{beta}-catenin pathway inhibitor calcimycin in colon cancer cells
Molecular Biology of the Cell 22 (18): 3344-3354 (2011-09)

Sack U.; Walther W.; Scudiero D.; Selby M.; Kobelt D.; Lemm M.; Fichtner I.; Schlag P.M.; Shoemaker R.H.; Stein U.
Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer
Journal of the National Cancer Institute 103 (13): 1018-1036 (2011-07-06)

Orthmann A.; Fichtner I.; Zeisig R.
Improving the transport of chemotherapeutic drugs across the blood-brain barrier
Expert Review of Clinical Pharmacology 4 (4): 477-490 (2011-07)

Merk J.; Rolff J.; Dorn C.; Leschber G.; Fichtner I.
Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
European Journal of Cardio-Thoracic Surgery 40 (1): e29-e33 (2011-07)

Bergman A.M.; Adema A.D.; Balzarini J.; Bruheim S.; Fichtner I.; Noordhuis P.; Fodstad O.; Myhren F.; Sandvold M.L.; Hendriks H.R.; Peters G.J.
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
Investigational New Drugs 29 (3): 456-466 (2011-06)

Bachmeier B.; Fichtner I.; Killian P.H.; Kronski E.; Pfeffer U.; Efferth T.
Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells
PLoS ONE 6 (5): e20550 (2011-05-26)

Calderon M.; Welker P.; Licha K.; Fichtner I.; Graeser R.; Haag R.; Kratz F.
Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly (ethylene glycol) shell
Journal of Controlled Release 151 (3): 295-301 (2011-05-10)

Fichtner I.; Behrens D.; Claffey J.; Deally A.; Gleeson B.; Patil S.; Weber H.; Tacke M.
The antiangiogenic and antitumoral activity of titanocene Y* in vivo
Letters in Drug Design & Discovery 8 (4): 302-307 (2011-05)

Winsel S.; Sommer A.; Eschenbrenner J.; Mittelstaedt K.; Klar U.; Hammer S.; Hoffmann J.
Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells
PLoS ONE 6 (4): e19273 (2011-04-29)

Bijnsdorp I.V.; Schwendener R.A.; Schott H.; Fichtner I.; Smid K.; Laan A.C.; Schott S.; Losekoot N.; Honeywell R.J.; Peters G.J.
Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine
Investigational New Drugs 29 (2): 248-257 (2011-04)

Tan W.L.; Bhattacharya B.; Loh M.; Balasubramanian I.; Akram M.; Dong D.; Wong L.; Thakkar B.; Salto-Tellez M.; Soo R.A.; Fichtner I.; Iacopetta B.; Soong R.
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer
Cancer Biology & Therapy 11 (6): 599-608 (2011-03-15)

Stein U.; Arlt F.; Smith J.; Sack U.; Herrmann P.; Walther W.; Lemm M.; Fichtner I.; Shoemaker R.H.; Schlag P.M.
Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis
Neoplasia 13 (2): 131-144 (2011-02)

Wulf-Goldenberg A.; Eckert K.; Fichtner I.
Intrahepatically transplanted human cord blood cells reduce SW480 tumor growth in the presence of bispecific EpCAM/CD3 antibody
Cytotherapy 13 (1): 108-113 (2011-01)


Kobelt D.; Aumann J.; Fichtner I.; Stein U.; Schlag P.M.; Walther W.
Activation of the CMV-IE promoter by hyperthermia in vitro and in vivo: biphasic heat induction of cytosine deaminase suicide gene expression
Molecular Biotechnology 46 (2): 197-205 (2010-10)

Gerlach J.; Luebberstedt M.; Edsbagge J.; Ring A.; Hout M.; Baun M.; Rossberg I.; Knoespel F.; Peters G.; Eckert K.; Wulf-Goldenberg A.; Bjoerquist P.; Stachelscheid H.; Urbaniak T.; Schatten G.; Miki T.; Schmelzer E.; Zeilinger K.
Interwoven four-compartment capillary membrane technology for three-dimensional perfusion with decentralized mass exchange to scale up embryonic stem cell culture
Cells Tissues Organs 192 (1): 39-49 (2010-06)

Brueckner B.; Rius M.; Rivera Markelova M.; Fichtner I.; Hals P.A.; Sandvold M.L.; Lyko F.
Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy
Molecular Cancer Therapeutics 9 (5): 1256-1264 (2010-05)

Orthmann A.; Zeisig R.; Koklic T.; Sentjurc M.; Wiesner B.; Lemm M.; Fichtner I.
Impact of membrane properties on uptake and transcytosis of colloidal nanocarriers across an epithelial cell barrier model
Journal of Pharmaceutical Sciences 99 (5): 2423-2433 (2010-05)

Wenzel J.; Zeisig R.; Haider W.; Habedank S.; Fichtner I.
Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation
Breast Cancer Research and Treatment 121 (1): 13-22 (2010-05)

Fichtner I.; Claffey J.; Deally A.; Gleeson B.; Hogan M.; Rivera Markelova M.; Mueller-Bunz H.; Weber H.; Tacke M.
Antitumor activity of vanadocene Y and its selenocyanate derivative in xenografted CAKI-1 tumors in mice
Journal of Organometallic Chemistry 695 (8): 1175-1181 (2010-04-15)

Deak E.; Ruester B.; Keller L.; Eckert K.; Fichtner I.; Seifried E.; Henschler R.
Suspension medium influences interaction of mesenchymal stromal cells with endothelium and pulmonary toxicity after transplantation in mice
Cytotherapy 12 (2): 260-264 (2010-04)

Hammer S.; Sommer A.; Fichtner I.; Becker M.; Rolff J.; Merk J.; Klar U.; Hoffmann J.
Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer
Clinical Cancer Research 16 (5): 1452-1465 (2010-03-01)

Graeser R.; Esser N.; Unger H.; Fichtner I.; Zhu A.; Unger C.; Kratz F.
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model
Investigational New Drugs 28 (1): 14-19 (2010-02)

Adema A.D.; Laan A.C.; Myhren F.; Fichtner I.; Verheul H.M.; Sandvold M.L.; Peters G.J.
Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel
International Journal of Oncology 36 (1): 285-294 (2010-01-01)

Wenzel J.; Zeisig R.; Fichtner I.
Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions
Clinical and Experimental Metastasis 27 (1): 25-34 (2010-01)

Harnack U.; Eckert K.; Fichtner I.; Pecher G.
Comparison of the effect of orally administered soluble {beta}-(1-3),(1-6)-D-glucan and of G-CSF on the recovery of murine hematopoiesis
In Vivo 24 (1): 59-63 (2010-01)


Bracker T.U.; Sommer A.; Fichtner I.; Faus H.; Haendler B.; Hess-Stumpp H.
Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models
International Journal of Oncology 35 (4): 909-920 (2009-10)

Harnack U.; Eckert K.; Fichtner I.; Pecher G.
Oral administration of a soluble 1-3, 1-6 beta-glucan during prophylactic survivin peptide vaccination diminishes growth of a B cell lymphoma in mice
International Immunopharmacology 9 (11): 1298-1303 (2009-10)

Merk J.; Rolff J.; Becker M.; Leschber G.; Fichtner I.
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
European Journal of Cardio-Thoracic Surgery 36 (3): 454-459 (2009-09)

Abu Ajaj K.; Graeser R.; Fichtner I.; Kratz F.
In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B
Cancer Chemotherapy and Pharmacology 64 (2): 413-418 (2009-07)

Fritzmann J.; Morkel M.; Besser D.; Budczies J.; Kosel F.; Brembeck F.H.; Stein U.; Fichtner I.; Schlag P.M.; Birchmeier W.
A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential
Gastroenterology 137 (11): 165-175 (2009-07)

Heringer-Walther S.; Eckert K.; Schumacher S.M.; Uharek L.; Wulf-Goldenberg A.; Gembardt F.; Fichtner I.; Schultheiss H.P.; Rodgers K.; Walther T.
Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo
Haematologica 94 (6): 857-860 (2009-06)

Hoffmann J.; Fichtner I.; Lemm M.; Lienau P.; Hess-Stumpp H.; Rotgeri A.; Hofmann B.; Klar U.
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases
Neuro Oncology 11 (2): 158-166 (2009-04)

Wenzel J.; Zeisig R.; Fichtner I.
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation
International Journal of Pharmaceutics 370 (1-2): 121-128 (2009-03-31)

Diaz Miqueli A.; Rolff J.; Lemm M.; Fichtner I.; Perez R.; Montero E.
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
British Journal of Cancer 100 (6): 950-958 (2009-03-24)

Stein U.; Walther W.; Arlt F.; Schwabe H.; Smith J.; Fichtner I.; Birchmeier W.; Schlag P.M.
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis
Nature Medicine 15 (1): 59-67 (2009-01)

Yang J.X.; Fichtner I.; Becker M.; Lemm M.; Wang X.M.
Anti-proliferative efficacy of icariin on HepG2 hepatoma and its possible mechanism of action
American Journal of Chinese Medicine 37 (6): 1153-1165 (2009)

Rolff J.; Dorn C.; Merk J.; Fichtner I.
Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers
Journal of Oncology 2009: 814140 (2009)

Walther W.; Fichtner I.; Schlag P.M.; Stein U.S.
Nonviral jet-injection technology for intratumoral in vivo gene transfer of naked DNA
Methods in Molecular Biology 542: 195-208 (2009)


Koklic T.; Zeisig R.; Sentjurc M.
Interaction of alkylphospholipid liposomes with MT-3 breast-cancer cells depends critically on cholesterol concentration
Biochimica et Biophysica Acta - Biomembranes 1778 (12): 2682-2689 (2008-12)

Fichtner I.; Behrens D.; Claffey J.; Gleeson B.; Hogan M.; Wallis D.; Weber H.; Tacke M.
Antitumor activity of oxali-titanocene Y in xenografted CAKI-1 tumors in mice
Letters in Drug Design & Discovery 5 (8): 489-493 (2008-12)

Fichtner I.; Rolff J.; Soong R.; Hoffmann J.; Hammer S.; Sommer A.; Becker M.; Merk J.
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers
Clinical Cancer Research 14 (20): 6456-6468 (2008-10-15)

Bijnsdorp I.; Schwendener R.; Schott H.; Schott S.; Fichtner I.; Honeywell R.; Losekoot N.; Laan A.; Peters G.J.
In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine
Nucleic Acids Symposium Series 52: 651 (2008-09-08)

Goldin-Lang P.; Tran Q.V.; Fichtner I.; Eisenreich A.; Antoniak S.; Schulze K.; Coupland S.E.; Poller W.; Schultheiss H.P.; Rauch U.
Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis
Oncology Reports 20 (1): 123-128 (2008-07)

Ryppa C.; Mann-Steinberg H.; Fichtner I.; Weber H.; Satchi-Fainaro R.; Biniossek M.L.; Kratz F.
In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3
Bioconjugate Chemistry 19 (7): 1414-1422 (2008-07)

Fichtner I.
Praeklinische Daten als Grundlage fuer die Konzeption klinischer Studien [Preclinical data as basis for the design of clinical studies]
Onkologie 31 (Suppl. 2): 34-38 (2008-05)

Dowling C.M.; Claffey J.; Cuffe S.; Fichtner I.; Pampillon C.; Sweeney N.J.; Strohfeldt K.; Watson R.W.; Tacke M.
Antitumor activity of Titanocene Y in xenografted PC3 tumors in mice
Letters in Drug Design & Discovery 5 (2): 141-144 (2008-03)

Wulf-Goldenberg A.; Eckert K.; Fichtner I.
Cytokine-pretreatment of CD34(+) cord blood stem cells in vitro reduces long-term cell engraftment in NOD/SCID mice
European Journal of Cell Biology 87 (2): 69-80 (2008-02-14)

Stein U.; Walther W.; Stege A.; Kaszubiak A.; Fichtner I.; Lage H.
Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA
Molecular Therapy 16 (1): 178-186 (2008-01)


Bijnsdorp I.V.; Schwendener R.A.; Schott H.; Fichtner I.; Smid K.; Schott S.; Laan A.C.; Peters G.J.
In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine
Nucleosides Nucleotides & Nucleic Acids 26 (10-12): 1619-1624 (2007-12-05)

Bannon J.H.; Fichtner I.; O'Neill A.; Pampillon C.; Sweeney N.J.; Strohfeldt K.; Watson R.W.; Tacke M.; McGee M.M.
Substituted titanocenes induce caspase-dependent apoptosis in human epidermoid carcinoma cells in vitro and exhibit antitumour activity in vivo
British Journal of Cancer 97 (9): 1234-1241 (2007-11-05)

Schmid B.; Warnecke A.; Fichtner I.; Jung M.; Kratz F.
Development of albumin-binding camptothecin prodrugs using a peptide positional scanning library
Bioconjugate Chemistry 18 (6): 1786-1799 (2007-11)

Yde C.W.; Frogne T.; Lykkesfeldt A.E.; Fichtner I.; Issinger O.G.; Stenvang J.
Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT
Cancer Letters 256 (2): 229-237 (2007-10-28)

Thirunarayanan N.; Cifire F.; Fichtner I.; Posner S.; Benga J.; Reiterer P.; Kremmer E.; Koelble K.; Lipp M.
Enhanced tumorigenicity of fibroblasts transformed with human herpesvirus 8 chemokine receptor vGPCR by successive passage in nude and immunocompetent mice
Oncogene 26 (39): 5702-5712 (2007-08-23)

Behrens D.; Gill J.H.; Fichtner I.
Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells
Molecular and Cellular Endocrinology 274 (1-2): 19-29 (2007-08-15)

Warnecke A.; Fichtner I.; Sass G.; Kratz F.
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B
Archiv der Pharmazie 340 (8): 389-395 (2007-08)

Behrens D.; Lykkesfeldt A.E.; Fichtner I.
The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
Targeted Oncology 2 (3): 135-144 (2007-07)

Schmid B.; Chung D.E.; Warnecke A.; Fichtner I.; Kratz F.
Albumin-Binding Prodrugs of Camptothecin and Doxorubicin with an Ala-Leu-Ala-Leu-Linker That Are Cleaved by Cathepsin B: Synthesis and Antitumor Efficacy
Bioconjugate Chemistry 18 (3): 702-716 (2007-05)

Kaufner L.; Cartier R.; Wuestneck R.; Fichtner I.; Pietschmann S.; Bruhn H.; Schuett D.; Thuenemann A.F.; Pison U.
Poly(ethylene oxide)-block-poly(glutamic acid) coated maghemite nanoparticles: in vitro characterization and in vivo behaviour
Nanotechnology 18 (11): 115710 (2007-03-21)

Zeisig R.; Koklic T.; Wiesner B.; Fichtner I.; Sentjurc M.
Increase in fluidity in the membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and increased lung metastasis in NOD/SCID mice
Archives of Biochemistry and Biophysics 459 (1): 98-106 (2007-03-01)

Walther W.; Arlt F.; Fichtner I.; Aumann J.; Stein U.; Schlag P.M.
Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression
Molecular Cancer Therapeutics 6 (1): 236-243 (2007-01)


Shalapour S.; Zelmer A.; Pfau M.; Moderegger E.; Costa-Blechschmidt C.; van Landeghem F.K.; Taube T.; Fichtner I.; Buehrer C.; Henze G.; Seeger K.; Wellmann S.
The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo
Clinical Cancer Research 12 (18): 5526-5532 (2006-09-15)

Schanzer J.M.; Fichtner I.; Baeuerle P.A.; Kufer P.
Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells
Journal of Immunotherapy 29 (5): 477-488 (2006-09)

Einsiedel H.G.; Kawan L.; Eckert C.; Witt O.; Fichtner I.; Henze G.; Seeger K.
Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia
Leukemia 20 (8): 1435-1436 (2006-08)

Schlereth B.; Kleindienst P.; Fichtner I.; Lorenczewski G.; Brischwein K.; Lippold S.; Silva A.D.; Locher M.; Kischel R.; Lutterbuese R.; Kufer P.; Baeuerle P.A.
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
Cancer Immunology Immunotherapy 55: 785-796 (2006-07)

Walther W.; Minow T.; Martin R.; Fichtner I.; Schlag P.M.; Stein U.
Uptake, biodistribution, and time course of naked plasmid DNA trafficking after intratumoral in vivo jet injection
Human Gene Therapy 17 (6): 611-624 (2006-06-15)

Fichtner I.; Pampillon C.; Sweeney N.J.; Strohfeldt K.; Tacke M.
Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice
Anti-Cancer Drugs 17 (3): 333-336 (2006-03)

Brischwein K.; Schlereth B.; Guller B.; Steiger C.; Wolf A.; Lutterbuese R.; Offner S.; Locher M.; Urbig T.; Raum T.; Kleindienst P.; Wimberger P.; Kimmig R.; Fichtner I.; Kufer P.; Hofmeister R.; da Silva A.J.; Baeuerle P.A.
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
Molecular Immunology 43 (8): 1129-1143 (2006-03)

Michaelis M.; Fichtner I.; Behrens D.; Haider W.; Rothweiler F.; Mack A.; Cinatl J.; Doerr H.W.; Cinatl J.
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo
International Journal of Oncology 28 (2): 439-446 (2006-02)

Besada V.; Diaz M.; Becker M.; Ramos Y.; Castellanos-Serra L.; Fichtner I.
Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance
Proteomics 6 (3): 1038-1048 (2006-02)


Koklic T.; Pirs M.; Zeisig R.; Abramovic Z.; Sentjurc M.
Membrane switch hypothesis. 1. Cell density influences lateral domain structure of tumor cell membranes
Journal of Chemical Information and Modeling 45 (6): 1701-1707 (2005-11-28)

Kratz F.; Mansour A.; Soltau J.; Warnecke A.; Fichtner I.; Unger C.; Drevs J.
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen
Archiv der Pharmazie 338: 462-472 (2005-10-07)

Mravljak J.; Zeisig R.; Pecar S.
Synthesis and biological evaluation of spin-labeled alkylphospholipid analogs
Journal of Medicinal Chemistry 48 (20): 6393-6399 (2005-10-06)

Walther W.; Stein U.; Fichtner I.; Kobelt D.; Aumann J.; Arlt F.; Schlag P.M.
Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma
Molecular Therapy 12 (6): 1176-1184 (2005-09-29)

Keil C.; Zeisig R.; Fichtner I.
Effect of surface modified liposomes on the aggregation of platelets and tumor cells
Thrombosis and Haemostasis 94 (2): 404-411 (2005-08)

Sharma A.D.; Cantz T.; Richter R.; Eckert K.; Henschler R.; Wilkens L.; Jochheim-Richter A.; Arseniev L.; Ott M.
Human cord blood stem cells generate human cytokeratin 18-negative hepatocyte-like cells in injured mouse liver
American Journal of Pathology 167 (2): 555-564 (2005-08-01)

Carstanjen D.; Gross A.; Kosova N.; Fichtner I.; Salama A.
The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells
Transfusion 45: 1192-1200 (2005-07-01)

Berry J.M.; Bradshaw T.D.; Fichtner I.; Ren R.; Schwalbe C.H.; Wells G.; Chew E.H.; Stevens M.F.; Westwell A.D.
Quinols as novel therapeutic agents. 2.(1) 4-(1-arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents
Journal of Medicinal Chemistry 48: 639-644 (2005-01-27)

Henschler R.; Goettig S.; Junghahn I.; Bug G.; Seifried E.; Mueller A.M.; Fichtner I.
Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers
Leukemia Research 29 (10): 1191-1199 (2005-01-01)

Schlereth B.; Fichtner I.; Lorenczewski G.; Kleindienst P.; Brischwein K.; da Silva A.; Kufer P.; Lutterbuese R.; Junghahn I.; Kasimir-Bauer S.; Wimberger P.; Kimmig R.; Baeuerle P.A.
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct
Cancer Research 65: 2882-2889 (2005-01-01)

Walther W.; Stein U.; Siegel R.; Fichtner I.; Schlag P.M.
Use of the nuclease inhibitor aurintricarboxylic acid (ATA) for improved non-viral intratumoral in vivo gene transfer by jet-injection
Journal of Gene Medicine 7 (4): 477-485 (2005-01-01)

Becker M.; Sommer A.; Kraetzschmar J.R.; Seidel H.; Pohlenz H.D.; Fichtner I.
Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM
Molecular Cancer Therapeutics 4: 151-170 (2005-01-01)


Fichtner I.; Becker M.; Besada V.; Castellanos-Serra L.
Differential protein expression pattern in tamoxifen-sensitive and -resistant breast cancer xenografts
International Journal of Clinical Pharmacology and Therapeutics 42 (11): 632-634 (2004-11)

Warnecke A.; Fichtner I.; Garmann D.; Jaehde U.; Kratz F.
Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug Carboplatin designed as albumin-binding prodrugs
Bioconjugate Chemistry 15 (6): 1349-1359 (2004-11-01)

Fichtner I.; Monks A.; Hose C.; Stevens M.F.; Bradshaw T.D.
The experimental antitumor agents phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models
Breast Cancer Research and Treatment 87 (1): 97-107 (2004-09-01)

Zeisig R.; Rueckerl D.; Fichtner I.
Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo
Anti-Cancer Drugs 15 (7): 707-714 (2004-08-01)

Fichtner I.; Becker M.; Zeisig R.; Sommer A.
In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance
European Journal of Cancer 40 (6): 845-851 (2004-04)

Varvaresou A.; Iakovou K.; Gikas E.; Fichtner I.; Fiebig H.H.; Kelland L.R.; Double J.A.; Bibby M.C.; Hendriks H.R.
Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo
Anticancer Research 24 (2): 907-919 (2004-03)

Zeisig R.; Stahn R.; Wenzel K.; Behrens D.; Fichtner I.
Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro
Biochimica et Biophysica Acta - Biomembranes 1660 (1): 31-40 (2004-01-28)

Zeisig R.; Teppke A.D.; Behrens D.; Fichtner I.
Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro
Breast Cancer Research and Treatment 87 (3): 245-254 (2004-01-01)

Walther W.; Stein U.; Fichtner I.; Schlag P.M.
Low-volume jet injection for efficient nonviral in vivo gene transfer
Molecular Biotechnology 28 (2): 121-128 (2004-01-01)

Fichtner I.; Slisow W.; Gill J.; Becker M.; Elbe B.; Hillebrand T.; Bibby M.
Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas
European Journal of Cancer 40 (2): 298-307 (2004-01)


Fichtner I.; Reszka R.; Arndt D.; Zeisig R.
Animal experiments - An essential component for the development of liposomal anticancer agents
Journal of Liposome Research 13 (1): 9-15 (2003-12-03)

Mansour A.M.; Drevs J.; Esser N.; Hamada F.M.; Badary O.A.; Unger C.; Fichtner I.; Kratz F.
A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2
Cancer Research 63 (14): 4062-4066 (2003-07-15)

Erben U.; Thiel E.; Bittroff-Leben A.; Schoch C.; Fichtner I.; Durkop H.; Notter M.
CS-1, a novel c-kithi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity
International Journal of Cancer 105 (2): 232-240 (2003-06-10)

Fichtner I.; Paal K.; Borgmann A.; Badiali L.; Wurm R.; Henze G.
Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias-correlation to the expression of multidrug resistance proteins
Anticancer Research 23 (3): 2657-2664 (2003-05)

Dreier T.; Baeuerle P.A.; Fichtner I.; Gruen M.; Schlereth B.; Lorenczewski G.; Kufer P.; Lutterbuese R.; Riethmueller G.; Gjorstrup P.; Bargou R.C.
T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct1
Journal of Immunology 170 (8): 4397-4402 (2003-04-15)

Zeisig R.; Ress A.; Fichtner I.; Walther W.
Lipoplexes with alkylphospholipid as new helper lipid for efficient in vitro and in vivo gene transfer in tumor therapy
Cancer Gene Therapy 10 (4): 302-311 (2003-04)

Fichtner I.; Becker M.; Baumgart J.
Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL)
European Journal of Cancer 39 (6): 801-807 (2003-04)

Nitsche A.; Junghahn I.; Thulke S.; Aumann J.; Radonic A.; Fichtner I.; Siegert W.
Interleukin-3 promotes proliferation and differentiation of human hematopoietic stem cells but reduces their repopulation potential in NOD/SCID mice
Stem Cells 21 (2): 236-244 (2003-03)


Kratz F.; Warnecke A.; Scheuermann K.; Stockmar C.; Schwab J.; Lazar P.; Drueckes P.; Esser N.; Drevs J.; Rognan D.; Bissantz C.; Hinderling C.; Folkers G.; Fichtner I.; Unger C.
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound
Journal of Medicinal Chemistry 45 (25): 5523-5533 (2002-12-05)

Becker M.; Nitsche A.; Neumann C.; Aumann J.; Junghahn I.; Fichtner I.
Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems
British Journal of Cancer 87 (11): 1328-1335 (2002-11-18)

Koklic T.; Sentjurc M.; Zeisig R.
The influence of cholesterol and charge on the membrane domains of alkylphospholipid liposomes as studied by EPR
Journal of Liposome Research 12 (4): 335-352 (2002-11)

Naundorf S.; Preithner S.; Mayer P.; Lippold S.; Wolf A.; Hanakam F.; Fichtner I.; Kufer P.; Raum T.; Riethmueller G.; Baeuerle P.A.; Dreier T.
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment
International Journal of Cancer 100 (1): 101-110 (2002-07-01)

Walther W.; Stein U.; Fichtner I.; Voss C.; Schmidt T.; Schleef M.; Nellessen T.; Schlag P.M.
Intratumoral low-volume jet-injection for efficient nonviral gene transfer
Molecular Biotechnology 21 (2): 105-115 (2002-06-01)

Brunner N.; Double J.; Fichtner I.; Gescher A.; Newell D.; Oosterhuis W.; Price P.
The EORTC laboratory research division
European Journal of Cancer 38 (4): S14-S18 (2002-03)

Bradshaw T.D.; Bibby M.C.; Double J.A.; Fichtner I.; Cooper P.A.; Alley M.C.; Donohue S.; Stinson S.F.; Tomaszewjski J.E.; Sausville E.A.; Stevens M.F.G.
Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles
Molecular Cancer Therapeutics 1 (4): 239-246 (2002-02-01)

Harder F.; Henschler R.; Junghahn I.; Lamers M.C.; Mueller A.M.
Human hematopoiesis in murine embryos after injecting human cord blood-derived hematopoietic stem cells into murine blastocysts
Blood 99 (2): 719-721 (2002-01-15)

Zeisig R.; Stahn R.; Fichtner I.
Inhibition of carbohydrate mediated cell adhesion by liposomes as a possible way to prevent tumour metastasis
Cellular and Molecular Biology Letters 7 (2): 270-271 (2002)


Lode J.; Fichtner I.; Kreuter J.; Berndt A.; Diederichs J.E.; Reszka R.
Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models
Pharmaceutical Research 18 (11): 1613-1619 (2001-01-01)

Zeisig R.; Caemmerer B.
Liposomes in the food industry
Mircoencapsulation of Food Ingredients : 101-119 (2001-01-01)

Kisseleva E.; Becker M.; Lemm M.; Fichtner I.
Early macrophage and cytokine response during the growth of immunogenic and non-immunogenic murine tumors
Anticancer Research 21 (5): 3477-3484 (2001-01-01)

Zeisig R.; Stahn R.; Teppke A.D.; Arndt D.
Cancerostatic octadecylpiperidinoylphosphate liposomes: effect of composition on uptake by and toxicity to J774 mouse macrophage cells and MT1 breast cancer cells in vitro
Anti-Cancer Drug Design 16 (1): 19-26 (2001-01-01)

Araujo R.C.; Kettritz R.; Fichtner I.; Paiva A.C.M.; Pesquero J.B.; Bader M.
Altered neutrophil homeostasis in kinin B1 receptor deficient mice
Biological Chemistry 382: 91-95 (2001-01-01)

Roemer I.; Vogel T.; Otto A.; Fichtner I.; Klose J.
Analysis of mouse beta-haptoglobin chain by lectin affinoblotting detection
Electrophoresis 22: 3038-3042 (2001-01-01)

Walther W.; Stein U.; Fichtner I.; Schlag P.M.
In vivo Gentransfer nackter DNA in xenotransplantierte Kolonkarzinome in der Nude Maus mit Hilfe der Jet-Injektion [In vivo gene transfer of naked DNA into xenotransplanted colon carcinoma by jet-injection]
Chirurgisches Forum 30: 69-72 (2001-01-01)

Walther W.; Stein U.; Fichtner I.; Malcherek L.; Lemm M.; Schlag P.M.
Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology
Gene Therapy 8 (3): 173-180 (2001-01-01)

Zeisig R.; Mueller K.; Maurer N.; Arndt D.; Fahr A.
The composition-dependent presence of free (micellar) alkylphospholipid in liposomal formulations of octadecyl-1,1-dimethyl-piperidino-4-yl-phosphate affects its cytotoxic activity in vitro
Journal of Membrane Biology 182 (1): 61-69 (2001-01-01)

Nitsche A.; Becker M.; Junghahn I.; Aumann J.; Landt O.; Fichtner I.; Wittig B.; Siegert W.
Quantification of human cells in NOD/SCID mice by duplex real-time polymerase reaction
Haematologica 86: 693-699 (2001-01-01)

Pecher G.; Harnack U.; Guenther M.; Hummel M.; Fichtner I.; Schenk J.A.
Generation of an immortalized human CD4+ T cell clone inhibiting tumor growth in mice
Biochemical and Biophysical Research Communications 283 (4): 738-742 (2001-01-01)

Arndt D.; Zeisig R.; Bechtel D.; Fichtner I.
Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice
Drug Delivery 8: 1-7 (2001-01-01)

Stahn R.; Grittner C.; Zeisig R.; Karsten U.; Felix S.B.; Wenzel K.
Sialyl Lewisx-liposomes as vehicles for site-directed, E-selectin-mediated drug transfer into activated endothelial cells
Cellular and Molecular Life Sciences 58 (1): 141-147 (2001-01-01)

Fulda S.; Fichtner I.; Hero B.; Berthold F.
Preclinical and clinical aspects on the use of amifostine as chemoprotectorin neuroblastoma patients
Medical and Pediatric Oncology 36: 199-202 (2001-01-01)


Goan S.R.; Junghahn I.; Wissler M.; Becker M.; Aumann J.; Just U.; Martiny-Baron G.; Fichtner I.; Henschler R.
Donor stromal cells from human blood engraft in NOD/SCID mice
Blood 96: 3971-3978 (2000-12-01)

Borgmann A.; Baldy C.; von Stackelberg A.; Beyermann B.; Fichtner I.; Nuernberg P.; Henze G.
Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice
Pediatric Hematology and Oncology 17 (8): 635-650 (2000-12-01)

Warda M.; Zeisig R.
Phospholipid- and fatty acid-composition in the erythrocyte membrane of the one-humped camel [Camelus dromedarius] and its influence on vesicle properties prepared from these lipids
Deutsche Tieraerztliche Wochenschrift 107 (9): 368-373 (2000-09-01)

Walther W.; Stein U.; Fichtner I.; Alexander M.; Shoemaker R.H.; Schlag P.M.
mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors
Cancer Gene Therapy 7 (6): 893-900 (2000-06-01)

Naundorf H.; Becker M.; Lykkesfeldt A.E.; Elbe B.; Neumann C.; Buttner B.; Fichtner I.
Development and characterization of a tamoxifen resistant breast carcinoma xenograft
British Journal of Cancer 82 (11): 1844-1850 (2000-06-01)

Stahn R.; Zeisig R.
Cell adhesion inhibition by glycoliposomes: Effects of vesicle diameter and ligand density
Tumor Biology 21 (3): 176-186 (2000-05-01)

Naundorf H.; Jost-Reuhl B.; Becker M.; Reuhl T.; Neumann C.; Fichtner I.
Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations
Breast Cancer Research and Treatment 60 (1): 81-92 (2000-03-01)

Horber D.H.; Cattaneo-Pangrazzi R.M.C.; von Ballmoos P.; Schott H.; Ludwig P.S.; Eriksson S.; Fichtner I.; Schwendener R.A.
Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5' -> 5')-N4-octadecyl-1-beta-d-arabinofuranosylcytosine
Journal of Cancer Research and Clinical Oncology 126 (6): 311-319 (2000-01-01)

Kratz F.; Roth T.; Fichtner I.; Schumacher P.; Fiebig H.H.; Unger C.
In vitro and in vivo efficacy of acid-sensitive transferrin and albumin doxorubicin conjugates in a human xenograft panel and in the MDA-MB-435 mamma carcinoma model
Journal of Drug Targeting 8: 305-318 (2000-01-01)


Arndt D.; Zeisig R.; Fichtner I.; Teppke A.D.; Fahr A.
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice
Breast Cancer Research and Treatment 58 (1): 71-80 (1999-11)

Hoffmann J.; Schmidt-Peter P.; Haensch W.; Naundorf H.; Bunge A.; Becker M.; Fichtner I.
Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas
Clinical Cancer Research 5: 2198-2204 (1999-08-01)

Dehmel A.; Becker M.; Lemm M.; Fichtner I.
Expression of CD44 isoforms in human breast carcinoma xenografts is not influenced by the treatment of mice with cytostatics or (anti-) hormones
Anticancer Research 19: 1977-1987 (1999-05-01)

Mobest D.; Goan S.R.; Junghahn I.; Winkler J.; Fichtner I.; Hermann V.; Becker M.; de Lima-Hahn E.; Henschler R.
Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells
Stem Cells 17: 152-161 (1999-01-01)

Mrowietz U.; Schwenk U.; Maune S.; Bartels J.; Kuepper M.; Fichtner I.; Schroeder J.M.; Schadendorf D.
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice
British Journal of Cancer 79: 1025-1031 (1999-01-01)

Fichtner I.; Goan S.R.; Becker M.; Baldy C.; Borgmann A.; von Stackelberg A.; Henze H.
Transplantation of human haematopoietic or leukaemic cells into SCID and NOD/SCID mice
Relevance of Tumor Models for Anticancer Drug Development : 207-217 (1999-01-01)

Goan S.R.; Junghahn I.; Fichtner I.; Becker M.; Just U.; Moebest D.; Henschler R.
Ex vivo expanded CD34+ blood progenitor cells display lymphomyeloid plus stromal cell differentiation potential after transplantation into NOD/SCID mice
Relevance of Tumor Models for Anticancer Drug Development : 219-232 (1999-01-01)


Arndt D.; Zeisig R.; Fichtner I.
Alkylphospholipid liposomes: Preparation, properties and use in cancer research
Drugs of Today 34 Suppl. F: 83-96 (1998-12-01)

Zeisig R.; Arndt D.; Stahn R.; Fichtner I.
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid
Biochimica et Biophysica Acta - Biomembranes 1414 (1-2): 238-248 (1998-11-11)

Walther W.; Stein U.; Fichtner I.; Shoemaker R.H.; Alexander M.; Schlag P.M.
In vivo evaluation of a cytostatic drug-inducible vector for the expression of TNF-alpha
Proceedings of the American Association of Cancer Research 39: 520 (1998-01-01)

Brachwitz H.; Bergmann J.; Fichtner I.; Thomas Y.; Vollgraf C.; Langen P.; Berdel W.E.
1-beta-D-Arabinofuranosylcytosine-5'-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C
Journal of Lipid Research 39: 162-172 (1998-01-01)

Fabian H.; Wessel R.; Jackson M.; Schwartz A.; Lasch P.; Fichtner I.; Mantsch H.H.; Naumann D.
IR-spectroscopy and IR-microscopy of human breast tumors, xenografted breast tumors, and breast tumor cell lines
Infrared Spectroscopy: New Tool in Medicine. Proceedings of Infrared Spectroscopy: New Tool in Medicine : 28-30 January 1998, San Jose, California : [s.p.] (1998-01-01)

Walther W.; Stein U.; Fichtner I.; Naundorf H.; Alexander M.; Shoemaker R.H.; Schlag P.M.
In vivo evaluation of a drug-inducible vector system for the combined gene and chemotherapy of cancer
: 139-144 (1998-01-01)


Walther W.; Stein U.; Lemm M.; Naundorf H.; Fichtner I.
Development and characterization of novel multidrug resistant breast cancer lines
Proceedings of the American Association of Cancer Research 38: 484 (1997-01-01)

Stein U.; Walther W.; Lemm M.; Naundorf H.; Fichtner I.
Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo
International Journal of Cancer 72: 885-891 (1997-01-01)

Reszka R.; Fichtner I.; Goan S.R.; Rudolph M.; Winter R.
Encapsulation of the transition metal compounds Carboplatin (CP) and Lobaplatin (LP) in different types ofliposomes and their physico-chemical, biochemical and biological characterization
Bioinorganic Chemistry - Transition Metals in Biology and their Coordination in Chemistry : 145-166 (1997-01-01)

Fichtner I.; Dehmel A.; Naundorf H.; Finke L.H.
Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice
Anticancer Research 17: 3633-3646 (1997-01-01)

Grabowska E.; Eckert K.; Fichtner I.; Schulze-Forster K.; Maurer H.R.
Bromelain proteases suppress growth, invasion and lung metastasis of B16F10 mouse melanoma cells
International Journal of Oncology 11: 243-248 (1997-01-01)

Fichtner I.; Lemm M.; Becker M.; Berthold F.
Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas
Anti-Cancer Drugs 8: 174-181 (1997-01-01)

Reszka R.; Beck P.; Fichtner I.; Hentschel M.; Richter J.; Kreuter J.
Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice
Journal of Pharmacology and Experimental Therapeutics 280: 232-237 (1997-01-01)

Arndt D.; Zeisig R.; Eue I.; Sternberg B.; Fichtner I.
Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas
Breast Cancer Research and Treatment 43: 237-246 (1997-01-01)


Schadendorf D.; Kern M.A.; Artuc M.; Pahl H.L.; Rosenbach T.; Fichtner I.; Nuernberg W.; Stueting S.; von Stebut E.; Worm M.; Makki A.; Jurgovsky K.; Kolde G.; Henz B.M.
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo
Journal of Cell Biology 135 (6 Pt 2): 1889-1898 (1996-12)

Goan S.R.; Schwarz K.; von Harsdorf S.; von Schilling C.; Fichtner I.; Junghahn I.; Just U.; Herrmann F.
Fibroblasts retrovirally transfected with the human IL-3 gene initiate and sustain multilineage human hematopoiesis in SCID mice: comparison of CD34-enriched vs CD34-enriched and in vitro expanded grafts
Bone Marrow Transplantation 18: 513-519 (1996-09-01)

Vogel T.; Dehmel A.; Otto A.; Fichtner I.; Kaisers H.; Schlag P.M.
Detektion Mamma-Karzinom-spezifischer Proteine aus dem Serum xenotransplantierter Nacktmaeuse mittels differentieller zweidimensionaler Elektrophorese
Langenbecks Archiv fuer Chirurgie Suppl.I: 537-542 (1996-01-01)

Walther W.; Stein U.; Wendt J.; Shoemaker R.H.
Drug-inducible vector for the conditional expression of the human TNFalpha gene
Proceedings of the American Association of Cancer Research 37: 350 (1996-01-01)

Walther W.; Stein U.
Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting
Journal of Molecular Medicine 74: 379-392 (1996-01-01)

Walther W.; Stein U.
Targeted vectors for gene therapy of cancer and retroviral infections
Molecular Biotechnology 6: 267-286 (1996-01-01)

Bargou R.C.; Mapara M.Y.; Arnold W.; Daniel P.T.; Doerken B.
Xenotransplantation of a novel hodgkin cell line HD-MyZ into SCID mice
Immunodeficient Animals: Models in Cancer Research : 187-192 (1996-01-01)

Goan S.R.; Fichtner I.; Just J.; Krause K.P.; Karawajew L.; Schwarz K.; von Harsdorf R.; von Schilling C.; Herrmann F.
Peripheral blood stem cell-initiated human hematopoiesis in severe combined immunodeficient (SCID) mice is accelerated by a rat fibroblast cell line retrovirally transfected with the human IL-3 gene
Immunodeficient Animals: Models of Cancer Research : 171-175 (1996-01-01)

Stein U.; Walther W.; Shoemaker R.H.
Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells
Journal of the National Cancer Institute 88: 1383-1392 (1996-01-01)

Zeisig R.; Fichtner I.; Arndt D.
Preparation and properties of alkylphospholipid liposomes: a review
Cellular and Molecular Biology Letters 1: 447-457 (1996-01-01)

Stein U.; Walther W.; Shoemaker H.
Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance
British Journal of Cancer 74: 1384-1391 (1996-01-01)

Stein U.; Walther W.; Shoemaker R.H.
Vincristine induction of mutant and wild-type human multidrug-resitance promoters is cell- type-specific and dose-dependent
Journal of Cancer Research and Clinical Oncology 122: 275-282 (1996-01-01)

Stein U.; Shoemaker R.H.; Schlag P.M.
MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas
European Journal of Cancer 32 A: 86-92 (1996-01-01)

Arndt D.; Eue I.; Fichtner I.; Zeisig R.
Antineoplastic activity of alkylphosphocholines and alkylphosphochiline liposomes: A review of recent knowledge
: 141-144 (1996-01-01)

Shi D.F.; Bradshaw T.D.; Wrigley S.; McCall C.J.; Lelieveld P.; Fichtner I.; Stevens M.F.G.
Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo
Journal of Medicinal Chemistry 39: 3375-3384 (1996-01-01)

Schadendorf D.; Fichtner I.; Makki A.; Alijagic S.; Kuepper M.; Mrowietz U.; Henz B.M.
Metastatic potential of human melanoma cells in nude mice - characterisation of phenotype, cytokine secretion and tumour-associated antigens
British Journal of Cancer 74: 194-199 (1996-01-01)

Zeisig R.; Eue I.; Kosch M.; Fichtner I.; Arndt D.
Preparation and properties of sterically stabilized hexadecylphosphochiline (miltefosine)-liposomes and influence of this modification on macrophage activation
Biochimica et Biophysica Acta 1283: 177-184 (1996-01-01)

Kisseleva E.; Becker M.; Lemm M.; Fichtner I.
Involvement of macrophages and cytokines into rejection mechanism of the drug-resistant and immunogenic murine lymphoma P388/adria
Anticancer Research 16: 1971-1978 (1996-01-01)

Arnold W.; Koepf-Maier P.; Micheel B.
Immunodeficient Animals: Models for Cancer Research
: (1996-01-01)

Zschiesche W.; Naundorf H.; Reszka R.; Saul G.J.; Fichtner I.
Effects of liposomes with defined fatty acid composition on xenotransplanted human mammary carcinomas
Immunodeficient Animals: Models for Cancer Research 51: 138-141 (1996-01-01)

Fichtner I.; Naundorf H.; Saul G.J.; Zschiesche W.; Zeisig R.
Establishment and characterization of human xenotransplanted breast carcinoma lines: use for the screening of alkylphosphocholines (APC)
Immunodeficient Animals: Models for Cancer Research 51: 129-133 (1996-01-01)

Naundorf H.; Zschiesche W.; Reineke S.; Saul G.J.; Frege J.; Buettner B.; Fichtner I.
Influence of estradiol and tamoxifen on the growth and regulation of C-erbB-2, estradiol and progesterone receptors of mammary carcinoma 3366 transplanted into nude mice
Immunodeficient Animals: Models for Cancer Research 51: 134-137 (1996-01-01)

Hoffmann J.; Stein U.; Schmidt-Peter P.; Haensch W.; Naundorf H.; Scheper R.J.; Fichtner I.
Establishment and characterization of human sarcoma lines transplanted into nude mice
Immunodeficient Animals: Models for Cancer Research : 57-60 (1996-01-01)

Naundorf H.; Parczyk K.; Zschiesche W.; Reinecke S.; Buettner B.; Saul G.J.; Sinn B.; Fichtner I.
Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas
Journal of Cancer Research and Clinical Oncology 122: 14-20 (1996-01-01)


Goan S.R.; Fichtner I.; Just U.; Karawajew L.; Schultze W.; Krause K.P.; von Harsdorf S.; von Schilling C.; Herrmann F.
The severe combined immunodeficient-human peripheral blood stem cell (SCID-huPBSC) mouse: a xenotransplant model for huPBSC-initiated hematopoiesis
Blood 86 (1): 89-100 (1995-07-01)

Walther W.; Stein U.; Pfeil D.
Gene transfer of human TNFalpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity
International Journal of Cancer 61 (6): 832-839 (1995-01-01)

Naundorf H.; Zschiesche W.; Reszka R.; Fichtner I.
Influence of liposomes rich in unsaturated or saturated fatty acids on the growth of human xenotransplanted mammary carcinomas and on the levels of heart type fatty acid binding protein
In Vivo 9: 247-252 (1995-01-01)

Fichtner I.; Reszka R.; Goan S.R.; Naundorf H.; Hentschel M.
Pharmacological effects of carboplatin-liposomes (CPL) in mice: a review of present knowledge
Journal of Liposome Research 5: 75-89 (1995-01-01)

Fichtner I.; Reszka R.; Goan S.R.; Naundorf H.
Carboplatin-liposomes (CPL) in immunodeficient mice: improved antitumor activity for breast carcinomas and stimulationof hematopoiesis
Medical Oncology 11: 111-119 (1995-01-01)

Fabian H.; Jackson M.; Murphy L.; Watson P.H.; Fichtner I.; Mantsch H.H.
A comparative infrared spectroscopic study of human breast tumors and breast tumor cell xenografts
Biospectroscopy 1: 37-45 (1995-01-01)

Zeisig R.; Jungmann S.; Eue I.; Daemen T.; Fichtner I.; Nissen E.; Arndt D.
Macrophage mediated tumor toxicity of alkylphosphocholine liposomes
Phospholipids: Characterization, Metabolism, and Novel Biological Applications : Proceedings of the 6th International Colloquium : 126-133 (1995-01-01)

Arndt D.; Zeisig R.; Eue I.; Fichtner I.
Alkylphosphocholines and alkylphosphocholine liposomes
Journal of Liposome Research 5: 91-98 (1995-01-01)


Fichtner I.; Reszka R.; Becker M.; Lemm M.; Richter J.; Rudolph M.
Stimulation of hematopoiesis by carboplatin-liposomes
Journal of Liposome Research 4 (1): 43-69 (1994-03)

Zeisig R.; Jungmann S.; Fichtner I.; Daemen T.; Arndt D.
Cytotoxic effects of alkylphosphocholines or alkylphosphocholine-liposomes and macrophages on tumor cells
Anticancer Research 14: 1785-1790 (1994-01-01)

Eue I.; Zeisig R.; Jungmann S.; Fichtner I.; Arndt D.
Immunmodyfying properties of free and liposomal alkylphosphocholines
European Journal of Cell Biology 63: 16-16 (1994-01-01)

Fichtner I.; Stein U.; Hoffmann J.; Winterfeld G.; Pfeil D.; Hentschel M.
Characterization of four drug resistant P388 sublines: resistance/sensitivity in vivo, resistance- and proliferation-markers, immunogenicity
Anticancer Research 14: 1995-2004 (1994-01-01)

Uckert W.; Asche O.; Mahanty B.; Fichtner I.
Influence of different promoters on the expression of tumor necrosis factor alpha in LS174T human colon carcinoma cells
International Journal of Oncology 5: 865-871 (1994-01-01)

Naundorf H.; Fichtner I.; Elbe B.; Saul G.J.; Haensch W.; Zschiesche W.; Reinecke S.
Establishment and characteristics of two new human mammary carcinoma lines in nude mice with special reference to the estradiol receptor status and the importance of stroma for in vivo and in vitro-growth
Breast Cancer Research and Treatment 32: 187-196 (1994-01-01)

Hoffmann J.; Stein U.; Schmidt-Peter P.; Haensch W.; Naundorf H.; Fichtner I.
Development and characterization of in vivo and in vitro tumor lines for investigation of the phenomenon of multidrug resistance in human sarcomas
Recent Advances in Chemotherapy. Proceedings of the 18th International Congress of Chemotherapy, Stockholm. : 885-887 (1994-01-01)

Fichtner I.; Zeisig R.; Naundorf H.; Jungmann S.; Arndt D.; Asongwe G.; Double J.A.; Bibby M.C.
Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro: use of liposomes
Breast Cancer Research and Treatment 32: 269-279 (1994-01-01)

Pfeil D.; Bergmann J.; Fichtner I.; Stein U.; Hentschel M.; Rothe I.; Goan S.R.
Multidrug resistance of murine leukemia cells characterization and correlation with cytochrome P-450 dependent activities, cytosolic calcium and cell cycle state
Anticancer Research 14: 571-576 (1994-01-01)


Walther W.; Fichtner I.; Uckert W.
Retrovirus-mediated gene transfer of tumor necrosis factor alpha into colon carcinoma cells generates a growth inhibition
Anticancer Research 13: 1565-1574 (1993-01-01)

Fichtner I.; Reszka R.; Schuett M.; Rudolph M.; Becker M.; Lemm M.; Richter J.; Berger I.
Carboplatin - liposomes as activators of hematopoiesis
Oncology Research 5: 65-74 (1993-01-01)

Beck P.; Kreuter J.; Reszka R.; Fichtner I.
Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models
Journal of Microencapsulation 10: 101-114 (1993-01-01)

Naundorf H.; Fichtner I.; Saul G.J.; Haensch W.; Buettner B.
Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice
Journal of Cancer Research and Clinical Oncology 119: 652-656 (1993-01-01)

Fichtner I.; Reipert B.; Becker M.; Lemm M.
In vivo characterization of immunogenicity of a mitoxantrone-resistant murine P388 leukemia
In Vivo 7 (1): 73-80 (1993-01)


Naundorf H.; Fichtner I.; Buettner B.; Frege J.
Establishment and characterization of a new human oestradiol- and progesteron-receptor-positive mammary carcinoma serially transplantable in nude mice
Journal of Cancer Research and Clinical Oncology 119: 35-40 (1992-01-01)

Winterfeld G.; Hauff P.; Goerlich M.; Arnold W.; Fichtner I.; Staab H.J.
Investigations of droloxifene and other hormone manipulations on N-nitrosomethylurea-induced rat mammary tumors. 1. Influence on tumor growth
Journal of Cancer Research and Clinical Oncology 119: 91-96 (1992-01-01)

Goerlich M.; Winterfeld G.; Hauff P.; Arnold W.; Fichtner I.; Staab H.J.
Investigations of droloxifene and other hormonal manipulations on N-nitrosomethylurea- induced rat mammary tumors. 2. Influence on estrogen receptor
Journal of Cancer Research and Clinical Oncology 119: 97-100 (1992-01-01)

Naundorf H.; Rewasowa E.C.; Fichtner I.; Buettner B.; Becker M.; Goerlich M.
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo-testing of ether lipids and their derivatives
Breast Cancer Research and Treatment 23: 87-95 (1992-01-01)

Fichtner I.; Kniest A.; Arndt D.
Measurements of carbon clearance in mice as toxicity parameter for liposomal preparations
In Vivo 6: 113-118 (1992-01-01)

van Borssum Waalkes M.; Fichtner I.; Dontjes B.; Lemm M.; Becker M.; Arndt D.; Scherphof G.L.
In vivo distribution and antitumor activity of liposomal 3',5'-0-dipalmitoyl-5-fluoro-2'-deoxyuridine
Journal of Microencapsulation 9: 335-346 (1992-01-01)


Fichtner I.; Arndt D.; Reszka R.; Gens J.
Pharmacokinetic behavior of 57CO-Bleomycin liposomes in mice: comparison with the unencapsulated substance
Anti-Cancer Drugs 2: 555-563 (1991-01-01)

Hoffmann J.; Fichtner I.; Becker M.; Lemm M.
Messung der Bromsulfaleinretention der Maus als moeglicher Parameter zur Einschaetzung der Leberfunktion nach Gabe liposomaler Praeparationen
Pharmazie 46: 222-223 (1991-01-01)

Zeisig R.; Fichtner I.; Arndt D.; Jungmann S.
Antitumor effects of alkylphosphocholines in different murine tumor models, use of liposomal preparations
Anti-Cancer Drugs 2: 411-417 (1991-01-01)

Ebert A.; Fichtner I.; Brandt R.; Buettner B.
Tierexperimentelle Untersuchungen mit dem Immunsuppressivum Cyclosporin A (CSA) an syngenen Tumormodellen
Archiv fuer Geschwulstforschung 61: 111-122 (1991-01-01)

Fichtner I.
Stellenwert von Tierversuchen in der Onkologie. Moegliche Alternativen?
Archiv fuer Geschwulstforschung 61: 153-161 (1991-01-01)